brought to you by I CORE







University of Dundee

Discovery and Optimisation of a Compound Series active against Trypanosoma cruzi, the causative agent of Chagas' Disease

Harrison, Justin R.; Sarkar, Sandipan; Hampton, Shahienaz; Riley, Jennifer; Stojanovski, Laste; Sahlberg, Christer

Published in: Journal of Medicinal Chemistry

10.1021/acs.jmedchem.9b01852

Publication date:

Document Version Peer reviewed version

Link to publication in Discovery Research Portal

Citation for published version (APA):

Harrison, J. R., Sarkar, S., Hampton, S., Riley, J., Stojanovski, L., Sahlberg, C., Appelqvist, P., Erath, J., Mathan, V., Rodriguez, A., Kaiser, M., Pacanowska, D. G., Read, K. D., Johansson, N. G., & Gilbert, I. H. (2020). Discovery and Optimisation of a Compound Series active against Trypanosoma cruzi, the causative agent of Chagas' Disease. *Journal of Medicinal Chemistry*, *63*(6), 3066-3089. https://doi.org/10.1021/acs.jmedchem.9b01852

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
 You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 24. May. 2021


Discovery and Optimisation of a Compound Series active against *Trypanosma cruzi,* the causative agent of Chagas' Disease

Justin R. Harrison,^a Sandipan Sarkar,^b Shahienaz Hampton,^a Jennifer Riley,^a Laste Stojanovski,^a Christer Sahlberg,^c Pia Appelqvist,^c Jessye Erath,^d Vinodhini Mathan,^b Ana Rodriguez,^d Marcel Kaiser,^{e,f} Dolores Gonzalez Pacanowska,^g Kevin D. Read,^a Nils Gunnar Johansson,^c Ian H. Gilbert^a


- a. Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, DD1 5EH, UK
 - b. Syngene International Ltd, Biocon Park , SEZ, Bommasandra Industrial Area Phase-IV, Bommasandra-Jigani Link Road, Bangalore 560 099, India
 - c. Medivir, Lunastigen 7, 141 44 Huddinge, Sweden
- d. New York University, 430 E. 29th st, Alexandria Center West Tower, room 511, lab 524, New York, NY 10010 , USA
- e. Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, Basel CH-4051, Switzerland
 - f. University of Basel, Petersplatz 1, Basel CH-4003, Switzerland
 - g. Instituto de Parasitología y Biomedicina "López-Neyra", Avda. Conocimiento S/N, Parque Tecnológico Ciencias de la Salud, 18016 Armilla, GRANADA, Spain

Contents:


HPLC traces for key compounds 10, 12, 17, 19, 42-48, 50, 51, 57, 58, and 89.




HPLC trace for compound 10




HPLC trace for compound 12





HPLC trace for compound 17






HPLC trace for compound 42







HPLC trace for compound 44




HPLC trace for compound 45







HPLC trace for compound 47




HPLC trace for compound 48







HPLC trace for compound 51



HPLC trace for compound 57





HPLC trace of compound 89